How to standardize and optimize the clinical practice pattern to improve diagnosis and treatment of age-related macular degeneration: interpretation of the Age-Related Macular Degeneration Guidelines of Royal College of Ophthalmologists

( views:376, downloads:0 )
Author:
WANG Feng-hua(Department of Ophthalmology, Affiliated First People’s Hospital, Shanghai Jiaotong University, Shanghai 200080, China)
SUN Xiao-dong(Department of Ophthalmology, Affiliated First People’s Hospital, Shanghai Jiaotong University, Shanghai 200080, China)
Journal Title:
Chinese Journal of Ocular Fundus Diseases
Issue:
Volume 28, Issue 05, 2012
DOI:
10.3760/cma.j.issn.1005-1015.2012.05.002
Key Word:
Macular degeneration/diagnosis; Macular degeneration/therapy; Choroidal neovascularization/drug therapy; Antibodies, monoclonal/therapeutic use; Editorial

Abstract: The diagnosis and treatment of age-related macular degeneration (AMD) is an international hotspot of eye research.Successful clinical applications of anti-VEGF drugs promoted both basic research and clinical practice of AMD.A number of countries and professional societies have established clinical guidelines for AMD management,including the epidemiology,risk factors,diagnosis,classification,and treatment process.These AMD guidelines are mostly based on recently published results of clinical trials,provided good model of evidence based medicine.It is urgent and necessary to have our own guideline which is suitable for Chinese patients.Reviewing and learning existed guidelines will help us to improve the clinical practice of AMD in China.

  • [1]Klein R,Klein BE,Tomany SC,et al.Ten-year incidence and progression of age-related maculopathy:The Beaver Dam eye study.Ophthalmology,2002,109:1767-1779.
  • [2]Wang J J,Foran S,Smith W,et al.Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation:the Blue Mountains Eye Study cohort.Arch Ophthalmol,2003,121:658-663.
  • [3]Mitchell P,Korobelnik JF,Lanzetta P,et al.Ranibizumab (Lucentis) in neovascular age-related macular degeneration:evidence from clinical trials.Br J Ophthalmol,2010,94:2-13.
  • [4]Bressler NM,Chang TS,Suner IJ,et al.Vision-related function after ranibizumab treatment by better-or worse-seeing eye:clinical trial results from MARINA and ANCHOR.Ophthalmology,2010,117:747-756.
  • [5]Rosenfeld PJ,Brown DM,Heier JS,et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med,2006,355:1419-1431.
  • [6]Brown DM,Kaiser PK,Michels M,et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med,2006,355:1432-1444.
  • [7]American Academy of Ophthalmology Retina panel.Preferred Practice Pattern(@) Guidelindes:age-related macular degeneration[EB/OL].San Francisco,CA:American Academy of Ophthalmology (AAO),2008.http://www.aao.org/PPP.
  • [8]Schmidt-Erfurth UM,Richard G,Augustin A,et al.Guidance for the treatment of neovascular age-related macular degeneration.Acta Ophthalmol Scand,2007,85:486-494.
  • [9]Age-related Macular Degeneration Guidelines for Management[EB/OL].London:The Royal College of Ophthalmologists,2009(2009-02).http://www.rcophth.ac.uk/page.asp? section =451 & sectionTitle =Clinical + Guidelines.
  • [10]Klein R,Davis MD,Magli YL,et al.The Wisconsin age-related maculopathy grading system.Ophthalmology,1991,98:1128-1134.
  • [11]The International ARM Epidemiological Study Group.An international classification and grading system for age-related maculopathy and age-related macular degeneration.Surv Ophthalmol,1995,39:367-374.
  • [12]Age-Related Eye Disease Study Research Group.The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs:the Age-Related Eye Disease Study Report Number 6.Am J Ophthalmol,2001,132:668-681.
  • [13]Tarita-Nistor L,Brent MH,Steinbach MJ,et al.Fixation patterns in maculopathy:from binocular to monocular viewing.Optom Vis Sci,2012,89:277-287.
  • [14]Takeuchi K,Kachi S,Iwata E,et al.Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration.Eye (Lond),2012,26:51-60.
  • [15]Neelam K,Nolan J,Chakravarthy U,et al.Psychophysical function in age-related maculopathy.Surv Ophthalmol,2009,54:167-210.
  • [16]Miller JW,Schmidt-Erfurth U,Sickenberg M,et al.Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration:results of a single treatment in phase 1 and 2 study.Arch Ophthalmol,1999,117:1161-1173.
  • [17]Schmidt-Erfurth U,Miller JW,Sickenberg M,et al.Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration:results of retreatments in a phase 1 and 2 study.Arch Ophthalmol,1999,117:1177-1187.
  • [18]Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin:one-year results of 2 randomized clinical trials-TAP report 1.Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.Arch Ophthalmol,1999,117:1329-1345.
  • [19]Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin:two-year results of 2 randomized clinical trials:TAP report 2.Arch Ophthalmol,2001,119:198-207.
  • [20]Bressler NM,Arnold J,Benchaboune M,et al.Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration:additional information regarding baseline lesion composition's impact on vision outcomes:TAP report No.3.Arch Ophthalmol,2002,120:1443-1454.
  • [21]Kaiser PK,Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration:5-year results of two randomized clinical trials with an open-label extension:TAP Report No.8.Graefe's Arch Clin Exp Ophthalmol,2006,244:1132-1142.
  • [22]Regillo CD,Brown DM,Abraham P,et al.Randomized,double-masked,sham-controlled trial of ranibizumab for neovascular age-related macular degeneration:PIER Study year 1.Am J Ophthalmol,2008,145:239-248.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn